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Abstract
Introduction: Erythropoiesis-Stimulating Agents (ESA) are hypothesized to increase cardiovascular mortality in patients with
chronic kidney disease. One of the proposed mechanisms is the elevation of blood pressure (BP) by ESA. Therefore, we
aimed to determine whether the use of ESA was associated with antihypertensive treatment and higher BP.
Materials and Methods: In this cohort 502 incident pre-dialysis patients were included who started specialized pre-dialysis
care in 25 clinics in the Netherlands. Data on medication including ESA use and dose, co-morbidities and BP were routinely
collected every 6 months. Antihypertensive treatment and BP were compared for patients with and without ESA at baseline.
Differences in antihypertensive medication and BP during pre-dialysis care were estimated with linear mixed models
adjusted for age, sex, body mass index, cardiovascular disease, diabetes mellitus and estimated glomerular filtration rate.
Results: At baseline, 95.6% of patients with ESA were treated with antihypertensive medication and 73.1% of patients
without ESA. No relevant difference in BP was found. During pre-dialysis care patients with ESA used 0.77 (95% CI 0.63;0.91)
more classes of antihypertensive drugs. The adjusted difference in systolic blood pressure (SBP) was 20.3 (95% CI 22.7;2.0)
mmHg and in diastolic blood pressure (DBP) was 21.0 (95% CI 22.1;0.3) mmHg for patients with ESA compared to patients
without ESA. Adjusted SBP was 3.7 (95% CI 21.6;9.0) mmHg higher in patients with a high ESA dose compared to patients
with a low ESA dose.
Conclusions: Our study confirms the hypertensive effect of ESA, since ESA treated patients received more antihypertensive
agents. However, no relevant difference in BP was found between patients with and without ESA, thus the increase in BP
seems to be controlled for by antihypertensive medication.
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Introduction
Hypertension is present in 71–95% of adult patients with
chronic kidney disease (CKD) [1–4]. High blood pressure (BP) is a
major risk factor for cardiovascular morbidity and mortality [5]
and is associated with an increased loss of renal function [6].
Therefore guidelines recommend a BP control to less than 130/
80 mmHg for patients with CKD [7–9].
With declining renal function, endogenous erythropoietin
production decreases and the majority of CKD patients will be
treated with erythropoiesis-stimulating agents (ESAs) for their
anemia. However, recently several anemia-correction trials in pre-
dialysis patients have demonstrated that patients randomized to
achieve normal hemoglobin levels experience more cardiovascular
events or a higher mortality rate [10–12]. These patients were
treated with higher ESA doses than patients assigned to the lower
hemoglobin arm. Some observational studies have also shown an
increased all-cause and cardiovascular mortality in dialysis patients
treated with higher ESA doses [13,14]. The mechanism respon-
sible for these excess cardiovascular events and mortality is not
entirely clarified. Several hypotheses have been proposed, but the
elevation of BP by ESAs thereby increasing the risk of
cardiovascular events is one of the most important theories
[15,16].
Indeed ESA induced hypertension has already been reported at
the introduction of ESAs late 1980s in 10–32% of hemodialysis
patients [17–19]. However, since then nephrologists have learned
to slowly increase hemoglobin with lower ESA doses to avoid these
side effects. Prior studies have also not consistently identified
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differences in BP in patients randomized to higher versus lower
hemoglobin targets [11,12,20,21]. In clinical practice actual BP
can remain stable during ESA treatment, with or without
adjustments in antihypertensive medication [19,22].
Data on BP control is limited in patients with CKD and the
available studies underrepresent the pre-dialysis patients [2–4,23–
25]. Most importantly, information about the influence of ESA
therapy and especially high doses of ESA therapy on BP is lacking.
Therefore we aimed to determine whether the use of ESA was
associated with antihypertensive treatment and higher BP.
Materials and Methods
Study Design and Population
The PREdialysis PAtient REcord (PREPARE-2) study is a
prospective follow-up study of incident pre-dialysis patients treated
in 25 nephrology outpatient clinics in the Netherlands. Patients of
at least eighteen years of age were included at the start of
specialized pre-dialysis care between July 2004 and June 2011. In
practice, this refers to incident pre-dialysis patients with an
estimated glomerular filtration rate (eGFR) of less than 20–
30 mL/min/1.73 m2, in whom renal function loss is progressive.
Patients with a failing kidney transplant were also included in the
study if the transplantation was at least one year ago. All
participants gave their written informed consent prior to study
inclusion. The patients were treated by their nephrologists in their
regular scheme according to the treatment guideline of the Dutch
Federation of Nephrology [26], a Dutch guideline based on the
KDOQI guidelines [7,27]. Clinical data were collected at the start
of specialized pre-dialysis care and in subsequent 6-month
intervals. Patients were followed until the start of dialysis,
transplantation, death, or censoring. Censoring was defined as
moving to an outpatient clinic not participating in the PREPARE-
2 study, recovery of renal function, refusal of further study
participation, lost to follow-up or reaching the end of follow-up at
August 1, 2012, whichever came first. The study was reviewed and
approved by the medical ethics committee of the Leiden
University Medical Center. The medical ethics committee or
institutional review board (as appropriate) of all participating
centers additionally reviewed and approved the local feasibility of
the study (see Supporting Information File S1).
Measurements and Definitions
Data on demography, primary kidney disease, co-morbidities
and medication use were collected at the start of specialized pre-
dialysis care and in subsequent 6-month intervals by the patients’
nephrologist or specialized nurse. Corresponding laboratory data
were extracted from the electronic hospital information systems or
medical records. Body mass index (BMI) was calculated as weight
(kg) divided by height (m) squared. Primary kidney disease was
classified according to the codes of the European Renal
Association-European Dialysis and Transplantation Association
and grouped into four categories (diabetes mellitus, glomerulone-
phritis, renal vascular disease and other) [28]. eGFR was
calculated using the abbreviated MDRD-formula, taking sex,
age, race and measured serum creatinine into account [29]. ESA
dose was registered in units per week, for darbepoetin dose in
micrograms was converted to units by multiplying with 200. ESA
dose was categorized in four subsequent dosing intervals: #2000
units/week, 2001–4000 units/week, 4001–6000 units/week and
.6000 units/week.
Outcome
Antihypertensive drugs were grouped into 8 classes (beta
blockers, calcium channel blockers, ACE inhibitors, angiotensin
receptor blockers, loop diuretics, other diuretics, alpha blockers
and others). Combination drugs were described in terms of their
components and then the number of antihypertensive drug classes
was counted. BP was measured as part of usual care by
nephrologists or clinical nurses in each outpatient clinic. In the
Netherlands, the standardized procedure for measuring BP is with
the use of cuff occlusion of the arm and auscultation when the
patient is in sitting position after five minutes of rest. With an
appropriate sized cuff at the height of the heart, at least two
measurements one to two minutes apart are performed. More
measurements are performed when the first two measurements are
clearly different and the mean of (the last) two values is noted [30].
Within BP targets was defined as a systolic blood pressure (SBP)
,130 mmHg and diastolic blood pressure (DBP) ,80 mmHg, as
recommended in guidelines [7–9].
Statistical Analyses
Baseline characteristics were presented for the total study
population and stratified for patients with and without ESA.
Continuous data were expressed as mean (standard deviation) and
categorical data as percentages. BP and antihypertensive medica-
tion was compared for patients with and without ESA at baseline
with an unpaired Student’s t-test or chi-square test. The effect of
ESA use and dose on the number of antihypertensive drug classes
or BP during pre-dialysis care was estimated using linear mixed
effects models. The models were used as repeated cross-sectional
analyses to estimate the difference in antihypertensive medication,
SBP and DBP between patients with and without ESA treatment.
To estimate the effect of ESA dose on BP, the difference in SBP
and DBP was also estimated in patients with ESA treatment in
subsequent dose intervals. To account for correlation between
measurements within the same patient a random intercept for
patients was applied. The models were checked for interaction
between time and ESA use or dose and eGFR and ESA use and
dose. The analyses were adjusted for age, sex, BMI, diabetes
mellitus, cardiovascular disease and eGFR. Of all BP measure-
ments at different time points during pre-dialysis care, corre-
sponding BMI was missing in 3.8% and eGFR in 25.7%. Missing
data on BMI and eGFR were imputed with standard multiple
imputation techniques in SPSS with 20 imputation sets, which are
based on the Markov Chain Monte Carlo (MCMC) method [31].
Sensitivity Analyses
To further quantify the intensity of antihypertensive drug
treatment, a standardized daily dose was calculated by dividing the
daily prescribed milligrams of drug by the drug’s defined daily
dose (DDD). DDD is the average daily dose of a drug taken by
adults for its main indication, developed by the World Health
Organization for use in drug utilization studies [32]. To obtain a
total standardized daily dose, all antihypertensive drug specific
standardized doses were added up, reflecting both the total
number and total dose of antihypertensive medication use. To
compare total standardized daily doses between patients with and
without ESA, a linear mixed model was used as described in the
previous section. Furthermore, a sensitivity analysis excluding
patients with a renal transplant was performed. The excluded
renal transplant patients were identified by their use of immuno-
suppressive medication.
All statistical analyses were performed with SPSS statistical
software, version 20 (IBM Corp, Armonk NY).
ESA and Blood Pressure in Pre-Dialysis Patients
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Results
Demographic and Clinical Characteristics
A total of 502 patients were included in the study, of which 205
(40.8%) patients were treated with ESA at the start of pre-dialysis
care. A summary of demographic and clinical characteristics at
baseline is shown in Table 1. Mean age was 64.9 years, 67.9% was
male and mean eGFR was 16.6 ml/min/1.73 m2. In ESA treated
patients mean eGFR was somewhat lower than in patients without
ESA treatment.
Hypertension Treatment and BP at Baseline
Antihypertensive medication was prescribed in 95.6% of ESA
treated patients as opposed to 73.1% of patients without ESA at
the start of pre-dialysis care (Table 2), and the number of
antihypertensive drug classes was generally higher. Mainly
angiotensin receptor blockers and loop diuretics were prescribed
more often in ESA treated patients. Distributions of SBP and DBP
at baseline are shown in Figure 1. Overall mean SBP was
142 mmHg and DBP was 78 mmHg, there was no difference in
patients with and without ESA. The percentage of patients within
BP targets (SBP#130 mmHg and DBP#80 mmHg) was the same
in patients with and without ESA. SBP was adequately controlled
in 26.7% of all patients, DBP in 50.6% and both in 20.3%.
ESA use and Antihypertensive Medication during Pre-
dialysis Care
The percentage of patients using ESA increased from 41% to
more than 50% within the first years of pre-dialysis care. Of the
patients that started dialysis, 58.3% was treated with ESA at their
last regular measurement before the start of dialysis. The
percentage of patients using antihypertensive medication increased
over time from 95.5% to 100% in ESA using patients and from
73.0% to 100% in patients without ESA.
Antihypertensive Medication during Pre-dialysis Care
Mean number of antihypertensive drug classes and BP in
patients with and without ESA treatment is shown in Table 3.
Patients with ESA treatment used more antihypertensive drugs to
control their BP, with an average difference of 0.77 drug classes
(95% confidence interval (CI) 0.63;0.91). This means that at least
three out of four patients with ESA were treated with one
antihypertensive class more than patients without ESA. Sensitivity
analysis with total standardized daily dose confirmed the increased
antihypertensive drug use: patients with ESA treatment were
treated with 1.61 (95% CI 1.12;2.10) standardized daily doses of
antihypertensive drugs more than patients without ESA treatment.
BP during Pre-dialysis Care
There was no relevant difference in measured SBP and DBP
during pre-dialysis care in patients with and without ESA
treatment. In ESA treated patients SBP was just 0.2 mmHg
higher (95% CI 22.1;2.5) and DBP 1.1 mmHg lower (95% CI
22.3;0.2) than in patients without ESA. Adjustment for age and
sex and further adjustment for BMI, diabetes mellitus, cardiovas-
cular disease and eGFR affected estimates just minimally. In
patients with ESA treatment however, patients treated with higher
ESA dose seemed to have on average higher BP, although
confidence intervals are wide (Table 4). Patients treated with an
ESA dose .6000 units/week had a 3.7 mmHg (95% CI 21.6;9.0)
higher SBP than patients treated with the lowest ESA dose
category. Differences in DBP were very small with 1.1 mmHg
(95% CI21.7;3.8) higher DBP in patients the highest ESA dose as
compared to the lowest. Results did not materially change with
further adjustment for hemoglobin and there was no significant
interaction between ESA use or dose and time or eGFR. In
addition, results were essentially the same when patients with a
renal transplant were excluded.
Discussion
This study showed an increased amount of antihypertensive
drugs in pre-dialysis patients with ESA as compared to patients
without ESA. This is in line with meta-analyses performed on trials
that compared patients with and without ESA, which identified a
26% to twofold increased risk for an increase in antihypertensive
agents in patients treated with ESA [33,34]. Meta-analyses of
anemia correction trials in CKD patients also reported a higher
risk for hypertension or hypertension adverse events (including an
escalation of the antihypertensive regimen) among patients treated
to higher hemoglobin targets, with on average higher ESA doses
[35,36]. Whereas our study did detect a difference in antihyper-
tensive medication, no relevant differences were found in routinely
measured BP between patients with and without ESA. This
confirms that in clinical practice actual BP can remain stable
during ESA treatment, with adjustments in antihypertensive
treatment [19,20,22,37]. Thus in our study population, physicians
were able to control BP in ESA treated patients to the same level
as patients without ESA treatment. It should be noted that in both
groups BP targets were hard to reach in clinical practice. In just
20.3% of patients BP was optimally controlled at the start of pre-
dialysis care, of which 26.7% met criteria for SBP and 50.6% for
DBP. This is in line with other reports in CKD patients [2,23–25]
and in pre-dialysis patients specifically [4].
The rise in BP during the use of ESA is multifactorial and
includes (among others) a direct effect on endothelial function
Table 1. Characteristics of patients with and without ESA at
the start of pre-dialysis care.
all patients No ESA ESA
Number 502 297 205
Age 64.9 (14.3) 64.4 (14.5) 65.7 (14.1)
Sex (% male) 67.9 67.7 68.3
BMI (kg/m2) 26.8 (5.2) 26.6 (5.3) 27.0 (5.0)
Primary kidney disease (%)
Diabetes mellitus 14.3 13.5 15.6
Glomerulonefritis 13.3 12.8 14.1
Renal vascular disease 30.7 30.3 31.2
Other 41.6 43.4 39.0
Comorbidity (%)
Diabetes Mellitus 26.3 24.2 29.3
Hypertension 83.2 84.8 80.9
Cardiovascular disease 41.2 43.4 38.0
eGFR (MDRD) mL/min/
1.73 m2
16.6 (5.9) 17.4 (5.8) 15.6 (6.0)
Albumin (g/L) 40.7 (4.6) 41.0 (4.7) 40.4 (4.4)
Hemoglobin (g/dL) 12.3 (1.5) 12.4 (1.5) 12.1 (1.4)
Values are presented as mean (standard deviation) or percentage.
Abbreviations: ESA = Erythropoiesis-Stimulating Agent, BMI = Body Mass Index,
eGFR = estimated Glomerular Filtration Rate.
doi:10.1371/journal.pone.0084848.t001
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[38]. ESA increases the expression of endothelin-1 in resistance
subcutaneous arteries from chronic kidney disease patients [39].
The rise in the patients’ BP could be attributed to the
vasoconstrictive effects of endothelin-1 [40]. ESA treated endo-
thelial cells also show a dose-dependent decrease in the
vasodilating nitric oxide [41]. In addition, elevation of BP usually
coincides with the rise in hematocrit and erythrocyte mass and
thereby the increase in blood viscosity. It is, however, also reported
that the increase in BP is independent of hematocrit [42].
ESA induced hypertension has already been reported in 10–
32% of hemodialysis patients at the introduction of ESA into
clinical practice [17–19]. Aside from the increased antihyperten-
sive drug use in patients with ESA, the BP raising effect of ESA is
also suggested in ESA treated patients in our study. Although
confidence intervals are wide, a trend towards higher BP with high
ESA dose is indicated. Other studies also reported higher
incidences of hypertension with increasing ESA doses [43] or a
dose dependent effect of ESA on DBP in hemodialysis patients
[44,45]. In pre-dialysis patients a secondary analysis of CHOIR
reported an association between increases in ESA dose and
increases in mainly DBP [21]. In this last report, however,
increases in DBP were not associated with the composite endpoint
of death, congestive heart failure hospitalization, stroke and
myocardial infarction.
The debate about the safety of ESAs was started after the
publication of several anemia correction trials in CKD patients in
which high hemoglobin targets and therefore higher ESA doses
were associated with increased mortality or cardiovascular events
[10–12,46]. The hypothesized mechanism for these adverse effects
includes the elevation of BP by ESA, besides changes in
endothelial function and effects of ESA on platelets and the
coagulation system [16,47].
Our results also support the hypothesis that ESA treatment
affects BP. However, it seems less likely that routinely measured
BP could explain a possible increase in cardiovascular events and
mortality in our population as the increase in BP seems to be
Figure 1. Distribution of systolic and diastolic blood pressure at baseline. The distribution of SBP and DBP are presented for the total
population and stratified by ESA use. The total percentage of patients within the blood pressure target (DBP: 80 mmHg and SBP: 130 mmHg) are
depicted in the histogram. Abbreviations: ESA= Erythropoiesis-Stimulating Agent, SBP= Systolic Blood Pressure, DBP=Diastolic Blood Pressure.
doi:10.1371/journal.pone.0084848.g001
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controlled for by antihypertensive medication. BP variability could
still play a role, since it is associated with mortality [48] and a peak
BP shortly after ESA administration is probably not captured in
our data.
Some limitations mainly because of the observational nature of
this study should be addressed. First, BP measurements reflect
measurements as routinely taken in clinical practice under the
influence of medication, both ESA and antihypertensive drugs and
including a possible white-coat effect. A previous study has
reported unchanged office BP after ESA treatment, but did detect
an increased level of BP measured at home in the morning [49].
Second, data on the interval between erythropoietin injection or
start of ESA treatment and BP measurement was lacking. ESA has
been reported to exert both an immediate effect as a long-term
effect on BP [38,45,50]. Since our analyses are cross-sectional in
nature, a causal relation between ESA and BP is hard to establish.
Table 2. Blood pressure and antihypertensive drugs in patients with and without ESA at the start of pre-dialysis care.
all patients No ESA ESA p
Number 502 297 205
Treated with antihypertensive drugs (%) 82.3 73.1 95.6 ,0.01
Number of antihypertensive drug classes (%)
0 17.7 26.9 4.4 ,0.01
1 11.6 8.8 15.6
2 21.9 20.2 24.4
3 23.5 20.9 27.3
4 16.9 15.8 18.5
5 6.6 5.7 7.8
6 1.8 1.7 2.0
Classes of drugs (%)
Beta blockers 46.0 45.5 46.8 0.76
Calcium channel blockers 46.6 43.1 51.7 0.06
ACE inhibitors 42.0 40.1 44.9 0.28
Angiotensin receptor blockers 37.5 31.0 46.8 ,0.01
Loop diuretics 35.5 27.3 47.3 ,0.01
Other diuretics 19.7 19.2 20.5 0.72
Alpha blockers 8.0 5.7 11.2 0.03
Others 1.8 2.0 1.5 0.64
SBP 142 (22) 143 (23) 142 (21) 0.86
DBP 78 (12) 78 (12) 78 (11) 0.68
Within BP targets (%) 20.3 20.6 19.8 0.83
Values are presented as mean (standard deviation) or percentage. Differences between patients with and without ESA were tested with a t-test or chi square test, as
appropriate.
Abbreviations: ESA = Erythropoiesis-Stimulating Agent, ACE =Angiotensin Converting Enzyme, SBP = Systolic Blood Pressure, DBP =Diastolic Blood Pressure, BP = Blood
Pressure.
doi:10.1371/journal.pone.0084848.t002
Table 3. Difference in antihypertensive drugs and BP in patients with and without ESA.
ESA Unadjusted Adjusted1 Adjusted2
Number of antihypertensive No ref ref ref
drug classes Yes 0.79 (0.64;0.93) 0.78 (0.64;0.92) 0.77 (0.63;0.91)
SBP (mmHg) No ref ref ref
Yes 0.2 (22.1;2.5) 0.0 (22.3;2.3) 20.3 (22.7;2.0)
DBP (mmHg) No ref ref ref
Yes 21.1 (22.3;0.2) 20.9 (22.1;0.3) 21.0 (22.1;0.3)
Values are presented as mean difference in number of antihypertensive drugs or difference in blood pressure (with 95% Confidence Interval).
1Adjusted for age and sex.
2Adjusted for age, sex, BMI, Diabetes Mellitus, Cardiovascular disease, eGFR.
Abbreviations: ESA = Erythropoiesis-Stimulating Agent, SBP = Systolic Blood Pressure, DBP =Diastolic Blood pressure, ref = Reference, BMI = Body Mass Index,
eGFR = estimated Glomerular Filtration Rate.
doi:10.1371/journal.pone.0084848.t003
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Third, different types of ESA were analyzed together. Previously
no difference in BP response between darbepoetin or epoetin in
pre-dialysis patients was reported [36,51], and although numbers
are small, a stratified analysis according to type of ESA in our data
showed the same trend. Fourth, although the increase in
antihypertensive medication was shown to the best of our abilities
by an increase in antihypertensive drug types and confirmed by an
increase in total standardized daily dose, the exact amount of drug
use remains difficult to compare between groups. Adding up
percentages of defined daily doses of different antihypertensive
drugs is a rough estimate, since for some antihypertensive drug
classes the dose in clinical practice can easily exceed the defined
daily dose, while for others it rarely does. Last, in our observational
study patients were not randomly allocated to a certain ESA
treatment. The observational nature of our study therefore
requires careful adjustment for confounding, which we executed
the best we could, but residual confounding cannot be excluded.
In summary, in this prospective cohort of pre-dialysis patients
we showed that ESA treated patients received more antihyper-
tensive agents and no difference in routinely measured BP between
patients with and without ESA was found. This means that the
hypertensive effect of ESA, as also illustrated by the trend towards
higher BP with high ESA dose, can be controlled to the same
extent as patients without ESA in clinical practice. It seems
therefore questionable from our results that this effect could
contribute to the increased cardiovascular risk associated with ESA
use in pre-dialysis patients. Trials evaluating the ESA-induced risk
of cardiovascular events should assess whether this risk was
mediated by elevated BP and the influence of other mechanisms
should be investigated.
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